Overview of biomarkers (currently only available in German language)


What does this portal do?

As the challenges of Individualized Medicine continue to increase with regard to precision-guided therapy, information on the use of appropriate biomarkers is becoming increasingly important. The collaboration of pathologists, oncologists, molecular biologists and human geneticists is becoming increasingly crucial for planning therapy as precisely as possible.

QuIP has set itself the task of accompanying pathologists in Germany and Europe in optimizing their examination results and supporting them in all relevant professional and organizational quality assurance activities. The Breast-Cancer-Portal is intended to serve pathologists as well as specialists in other disciplines and oncologists for orientation at the interface between biomarker testing and therapy.

Two biomarker-based treatment algorithms for Early Breast Cancer and Advanced/Metastatic Breast Cancer are provided on the Breast-Cancer-Portal, based on both current medical guideline recommendations and new scientific evidence, with detailed explanations of the underlying tests. Information on biomarkers, tests, analyses, and treatment options is shown so that pathologists and oncology physicians can obtain compact information on this topic and the therapeutic implications.

Additional information can be found at the German Arbeitsgemeinschaft Gynäkologische Onkologie (AGO Recommendations). The S3 guideline Breast Cancer can be found on the website of the German Association of the Scientific Medical Societies (AWMF).

Although it is currently only available in German language, please check back periodically or sign up for our newsletter to be informed as soon as the portal is available in English.

References on the portal

The underlying and used scientific literature for the Breast-Cancer-Portal content is cited for the respective algorithm passages as a list in a separate Literature tab and cited and identified in the continuous texts. The research literature listed there refers in each case to the processing status of the portal editors and is ­– where necessary – continuously updated or supplemented.


Please note: The information on the Breast-Cancer-Portal is provided to the best of our knowledge. However, please note that we cannot guarantee the completeness, accuracy and/or timeliness of the information. This applies in particular to content on our website that does not originate from us but from third parties and is only linked by us. For current and also further information on the preparations, the respective technical information should be consulted.

In addition, the subject matter is generally characterized by the fact that different pathologists may arrive at different results in the detailed diagnosis of images. Therefore, in the reference sections, we always indicate the concrete data basis on which the evaluation of the section is based. The evaluation of your own specimens is your sole responsibility. Please feel free to contact us at any time if you have any questions.

Data protection

Data protection in Germany prevents QuIP from publicly sharing the Breast-Cancer-Portal and the link to the website. Only the introduction can be seen on the portal start page, all other content is only available to medical professionals.

Registered QuIP users will automatically find a link to the Breast-Cancer-Portal after logging in on the QuIP homepage. All physicians who have DocCheck access will also have access to the Breast-Cancer-Portal. All other interested parties without a QuIP account or DocCheck access can request access to the portal by sending an e-mail to QuIP. An access code will be provided once the requestor’s access requirements are checked.

The QuIP is supported by AstraZeneca, Lilly, Menarini StemlineMSD Sharp & Dohme, Pierre Fabre and Sanofi.

Status: May 2024